{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:09:53Z","timestamp":1773936593583,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB0830000"],"award-info":[{"award-number":["XDB0830000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073875"],"award-info":[{"award-number":["82073875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118507","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T16:12:04Z","timestamp":1766247124000},"page":"118507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance"],"prefix":"10.1016","volume":"304","author":[{"given":"Yuting","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiajuan","family":"Huan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xubin","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxue","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-5808","authenticated-orcid":false,"given":"Chunhao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118507_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.02.005","article-title":"Aberrations in DNA repair pathways in cancer and therapeutic significances","volume":"58","author":"Motegi","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118507_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","article-title":"Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors","volume":"66","author":"Lord","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118507_bib3","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118507_bib4","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.ejmech.2025.118507_bib5","doi-asserted-by":"crossref","first-page":"16711","DOI":"10.1021\/acs.jmedchem.1c01522","article-title":"Discovery of Quinazoline-2,4(1H,3H)-dione derivatives containing 3-Substituted piperizines as potent PARP-1\/2 inhibitors horizontal line design, synthesis, in vivo antitumor activity, and X-ray crystal structure analysis","volume":"64","author":"Zhou","year":"2021","journal-title":"J. Med. Chem."},{"issue":"7035","key":"10.1016\/j.ejmech.2025.118507_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.ejmech.2025.118507_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/1535-7163.MCT-23-0625","article-title":"The discovery of a potent PARP1 inhibitor senaparib","volume":"24","author":"Cai","year":"2025","journal-title":"Mol. Cancer Therapeut."},{"issue":"10","key":"10.1016\/j.ejmech.2025.118507_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s40265-021-01570-6","article-title":"Fuzuloparib: first approval","volume":"81","author":"Lee","year":"2021","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118507_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","article-title":"Niraparib: first global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118507_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1158\/2159-8290.CD-NB2015-011","article-title":"Olaparib approved for advanced ovarian cancer[J]","volume":"5","year":"2015","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118507_bib12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","article-title":"Pamiparib: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118507_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/2159-8290.CD-NB2016-164","article-title":"Rucaparib approved for ovarian cancer","volume":"7","author":"Rose","year":"2017","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.ejmech.2025.118507_bib14","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","article-title":"Talazoparib: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.ejmech.2025.118507_bib16","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.ejmech.2025.118507_bib18","doi-asserted-by":"crossref","first-page":"8412","DOI":"10.3390\/ijms23158412","article-title":"PARP inhibitors: clinical limitations and recent attempts to overcome them","volume":"23","author":"Kim","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118507_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.05.008","article-title":"Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"33","author":"Gogola","year":"2018","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib21","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","article-title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer","volume":"31","author":"Waks","year":"2020","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.118507_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.7150\/jca.65650","article-title":"Comprehensive analysis of somatic reversion mutations in homologous recombination repair (HRR) genes in a large cohort of chinese pan-cancer patients","volume":"13","author":"Zong","year":"2022","journal-title":"J. Cancer"},{"issue":"10","key":"10.1016\/j.ejmech.2025.118507_bib23","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/0008-5472.CAN-20-2912","article-title":"Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells","volume":"81","author":"F\u00e4rkkil\u00e4","year":"2021","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118507_bib24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ncb3626","article-title":"EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation","volume":"19","author":"Rondinelli","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118507_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2020.08.018","article-title":"PCAF-mediated histone acetylation promotes replication fork degradation by MRE11 and EXO1 in BRCA-deficient cells","volume":"80","author":"Kim","year":"2020","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.ejmech.2025.118507_bib26","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.7150\/ijbs.41395","article-title":"Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging","volume":"16","author":"Morosi","year":"2020","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.jmedchem.9b00622","article-title":"Discovery of novel dual poly(ADP-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2025.118507_bib28","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2021.39.15_suppl.5505","article-title":"Effort: efficacy of adavosertib in parp resistance: a randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer","volume":"39","author":"Westin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118507_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor\u2013resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118507_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/0008-5472.CAN-21-0732","article-title":"Repurposing ceritinib induces DNA damage and enhances PARP inhibitor responses in high-grade serous ovarian carcinoma","volume":"82","author":"Kanakkanthara","year":"2022","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12272-024-01494-1","article-title":"Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress","volume":"47","author":"Liu","year":"2024","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"18","key":"10.1016\/j.ejmech.2025.118507_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810503","article-title":"Combined PARP and dual topoisomerase inhibition potentiates genome instability and cell death in ovarian cancer","volume":"23","author":"Fl\u00f6rkemeier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118507_bib33","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/acs.jmedchem.1c00932","article-title":"Discovery of a dual tubulin and poly(ADP-Ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12967-021-03073-0","article-title":"Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer","volume":"19","author":"Meng","year":"2021","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib35","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib36","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.ejmech.2025.118507_bib37","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.2174\/138161209788453266","article-title":"Designed multiple ligands: an emerging anti-HIV drug discovery paradigm","volume":"15","author":"Zhan","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib38","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual poltheta\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.118507_bib39","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118507_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116739","article-title":"Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers","volume":"61","author":"Lin","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118507_bib41","doi-asserted-by":"crossref","first-page":"12284","DOI":"10.1021\/acs.jmedchem.3c00821","article-title":"YCH1899, a highly effective phthalazin-1(2H)-one derivative that overcomes resistance to prior PARP inhibitors","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.118507_bib42","first-page":"2813","article-title":"Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors","volume":"10","author":"Chen","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118507_bib43","first-page":"9771","article-title":"Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage","volume":"44","author":"Steffen","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118507_bib44","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/ijc.32131","article-title":"Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity","volume":"145","author":"Chen","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118507_bib45","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/cas.13477","article-title":"Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib46","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10637-021-01096-4","article-title":"Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers","volume":"39","author":"Li","year":"2021","journal-title":"Invest. N. Drugs"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118507_bib47","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41419-021-03475-4","article-title":"Glycogen synthase kinase 3\u03b2 inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer","volume":"12","author":"Zhang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"29","key":"10.1016\/j.ejmech.2025.118507_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501916","article-title":"Novel ATR\/PARP1 dual inhibitors demonstrate synergistic antitumor efficacy in triple-negative breast cancer models","volume":"12","author":"Gao","year":"2025","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118507_bib49","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.18632\/oncotarget.13749","article-title":"Novel PARP1\/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution","volume":"8","author":"He","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118507_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2016.11.010","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials","volume":"386","author":"Yuan","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118507_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118273","article-title":"Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway","volume":"189","author":"Jaidee","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41392-025-02271-2","article-title":"Dual ENPP1\/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer","volume":"10","author":"Ruiz-Fern\u00e1ndez De C\u00f3rdoba","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"5","key":"10.1016\/j.ejmech.2025.118507_bib53","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.celrep.2013.04.018","article-title":"Two distinct modes of ATR activation orchestrated by Rad17 and Nbs1","volume":"3","author":"Shiotani","year":"2013","journal-title":"Cell Rep."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118507_bib54","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1158\/1078-0432.CCR-22-0875","article-title":"Targeting the DNA damage response pathways and replication stress in colorectal cancer","volume":"28","author":"Durinikova","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118507_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215919","article-title":"PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer","volume":"550","author":"Shen","year":"2022","journal-title":"Cancer Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2025.118507_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.165268","article-title":"Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS\/STING pathway","volume":"8","author":"Dong","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib57","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-019-11048-5","article-title":"BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors","volume":"10","author":"Reisl\u00e4nder","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib58","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/s41598-019-38534-6","article-title":"Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib59","doi-asserted-by":"crossref","first-page":"6676","DOI":"10.1038\/s41467-024-50999-2","article-title":"53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2020.01.030","article-title":"Combination therapy with radiation and PARP inhibition enhances responsiveness to Anti-PD-1 therapy in colorectal tumor models","volume":"108","author":"Seyedin","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118507_bib61","article-title":"Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer","volume":"9","author":"Mohamed","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118507_bib62","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202216235","article-title":"Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance","volume":"15","author":"Wang","year":"2023","journal-title":"EMBO Mol. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118507_bib63","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1021\/jm301825t","article-title":"Design, synthesis, and biological evaluation of a series of Benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors","volume":"56","author":"Ye","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:17:56Z","timestamp":1773929876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":63,"alternative-id":["S0223523425012723"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118507","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of novel PARP inhibitors against acquired drug-resistance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118507"}}